Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients With Type 1 And Type 2 Diabetes
Links shared publicly online about this topic.
- 195total visits
Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients With Type 1 And Type 2 Diabetes
Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine,
View full resource at medicalnewstoday.com
Tags: Diabetes, Blood Sugar, Insulin, Type 2 Diabetes, Low Blood Sugar, Novo Nordisk
Most Recently Shared on June 24, 2011 at 10:37 pm By:
Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients Wi.. http://dld.bz/ae5PX
Also Shared By:
Advertisement
MNT Diabetes News
@mnt_diabetes
Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients Wi... http://mnt.to/3XF8
1 year ago...